Patient Approach in Advanced/Metastatic Renal Cell Carcinoma
In the last few years six new treatments were approved to treat mRCC, and some others, such as tivozanib, dovitinib and nivolumab, are in clinical development. Competition for market share is intense for all molecules and the selection of the optimal treatment for a given patient will likely become more complex for physicians. We believe that the identification of biomarkers to better identify patients who are likely to benefit from a given agent will have great importance in the years to come. Finally, recommendations from Phase III trials (ASSURE, SORCE, TRAC, PROTECT and EVEREST) on the neoadjuvant/adjuvant use of targeted therapy in mRCC are eagerly awaited.
Future Perspective
In the last few years six new treatments were approved to treat mRCC, and some others, such as tivozanib, dovitinib and nivolumab, are in clinical development. Competition for market share is intense for all molecules and the selection of the optimal treatment for a given patient will likely become more complex for physicians. We believe that the identification of biomarkers to better identify patients who are likely to benefit from a given agent will have great importance in the years to come. Finally, recommendations from Phase III trials (ASSURE, SORCE, TRAC, PROTECT and EVEREST) on the neoadjuvant/adjuvant use of targeted therapy in mRCC are eagerly awaited.
SHARE
![Pediatric Supportive Care (PDQ®): Supportive care - Patient Information [NCI]-Overview](https://cdnus.oss-us-west-1.aliyuncs.com/libs/images/NewsJpg/cate_6/072_215x160.jpg)
